Literature DB >> 16400019

Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.

Lucia E Rosas1, Anjali A Satoskar, Kimberly M Roth, Tracy L Keiser, Joseph Barbi, Christopher Hunter, Frederic J de Sauvage, Abhay R Satoskar.   

Abstract

The interleukin-27 (IL-27)/T-cell cytokine receptor (TCCR) pathway plays an important role in development of protective immunity against cutaneous leishmaniasis caused by Leishmania major. In this study, we analyzed the role of IL-27/TCCR pathway in the host defense against visceral leishmaniasis (VL) by monitoring the course of L. donovani infection in TCCR-deficient C57BL/6 (TCCR-/-) mice. TCCR-/- mice mounted a robust inflammatory response, produced high levels of pro-inflammatory cytokines, and developed severe liver pathology after L. donovani infection that eventually resolved. Interestingly, L. donovani-infected TCCR-/- mice controlled the parasite growth in their organs significantly faster than similarly infected TCCR+/+ mice. Adoptive cell transfer and cell depletion studies revealed that CD4(+) T cells were involved in mediating liver immunopathology and controlling L. donovani growth in TCCR-/- mice. These results indicate that the IL-27/TCCR pathway is not essential for the induction of protective Th1 response during VL but is involved in mediating susceptibility to L. donovani. Additionally, the data demonstrate that although the IL-27/TCCR interaction limits the severity of liver inflammation during VL by controlling CD4(+) T-cell activity, it is not required for the resolution of hepatic immunopathology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16400019      PMCID: PMC1592683          DOI: 10.2353/ajpath.2006.050013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.

Authors:  J Alexander; K C Carter; N Al-Fasi; A Satoskar; F Brombacher
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

2.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

3.  WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27.

Authors:  Stefan Pflanz; Linda Hibbert; Jeanine Mattson; Rency Rosales; Elena Vaisberg; J Fernando Bazan; Joseph H Phillips; Terrill K McClanahan; Rene de Waal Malefyt; Robert A Kastelein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

4.  Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses.

Authors:  Simona Stäger; James Alexander; Alun C Kirby; Marina Botto; Nico Van Rooijen; Deborah F Smith; Frank Brombacher; Paul M Kaye
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

5.  Sustained parasite burden in the spleen of Leishmania infantum-infected BALB/c mice is accompanied by expression of MCP-1 transcripts and lack of protection against challenge.

Authors:  D Rousseau; S Demartino; F Anjuère; B Ferrua; K Fragaki; Y Le Fichoux; J Kubar
Journal:  Eur Cytokine Netw       Date:  2001 Apr-Jun       Impact factor: 2.737

6.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

7.  A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.

Authors:  Tuhina Mazumdar; Khairul Anam; Nahid Ali
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

8.  Expression of IL-27 in human Th1-associated granulomatous diseases.

Authors:  Frédérique Larousserie; Stefan Pflanz; Aurore Coulomb-L'Herminé; Nicole Brousse; Rob Kastelein; Odile Devergne
Journal:  J Pathol       Date:  2004-02       Impact factor: 7.996

9.  WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production.

Authors:  Shinjiro Hamano; Kunisuke Himeno; Yoshiyuki Miyazaki; Kazunari Ishii; Atsushi Yamanaka; Atsunobu Takeda; Manxin Zhang; Hajime Hisaeda; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

10.  The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection.

Authors:  Alejandro Villarino; Linda Hibbert; Linda Lieberman; Emma Wilson; Tak Mak; Hiroki Yoshida; Robert A Kastelein; Christiaan Saris; Christopher A Hunter
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

View more
  67 in total

1.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  The IL-27 receptor has biphasic effects in crescentic glomerulonephritis mediated through Th1 responses.

Authors:  Shaun A Summers; Richard K S Phoon; Joshua D Ooi; Stephen R Holdsworth; A Richard Kitching
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.

Authors:  George D Kalliolias; Rachael A Gordon; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 4.  Negative regulation of Th17 responses.

Authors:  J S Stumhofer; J Silver; C A Hunter
Journal:  Semin Immunol       Date:  2008-01-24       Impact factor: 11.130

Review 5.  Interleukin-12 and tuberculosis: an old story revisited.

Authors:  Andrea M Cooper; Alejandra Solache; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

6.  IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Authors:  Nasim Akhtar Ansari; Rajiv Kumar; Shalini Gautam; Susanne Nylén; Om Prakash Singh; Shyam Sundar; David Sacks
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

7.  Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection.

Authors:  Asher Maroof; Paul M Kaye
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

8.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.

Authors:  Henry W Murray; Yunhua Zhang; Yan Zhang; Vanitha S Raman; Steven G Reed; Xiaojing Ma
Journal:  Infect Immun       Date:  2013-04-15       Impact factor: 3.441

9.  A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Gaurav Gupta; Kevin J Peine; Dalia Abdelhamid; Heidi Snider; Andrew B Shelton; Latha Rao; Sainath R Kotha; Andrew C Huntsman; Sanjay Varikuti; Steve Oghumu; C Benjamin Naman; Li Pan; Narasimham L Parinandi; Tracy L Papenfuss; A Douglas Kinghorn; Eric M Bachelder; Kristy M Ainslie; James R Fuchs; Abhay R Satoskar
Journal:  ACS Infect Dis       Date:  2015-09-21       Impact factor: 5.084

Review 10.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.